Regular updates related to C19RM are available on this page.
-
02 December 2021
The Global Fund Achieves Significant Price Reductions for Antigen Rapid Diagnostic Tests (Ag RDTS)
A new agreement reached by the Global Fund and several producers of COVID-19 antigen rapid diagnostic tests (Ag RDTs) has resulted in a significant drop in the price of these tests, potentially making the products more affordable for many governments... -
16 November 2021
Inequitable Access to COVID-19 Tools is Hindering the Pandemic Response
A new snapshot reveals the persistent and glaring inequity in access to lifesaving COVID-19 tools, such as diagnostic tests, treatments (including medical oxygen), and personal protective equipment (PPE), that is hindering the pandemic response in lo... -
03 November 2021
Briefing Note: Testing for both Tuberculosis and SARS-CoV-2
The new Briefing Note on Testing for both Tuberculosis and SARS-CoV-2 is now available, also in French and Spanish. It provides information for TB programs including testing for both diseases. -
03 September 2021
COVID-19 Response Mechanism Guidelines and Other Documents: Recent Updates
-
03 September 2021
Accelerating Procurement of Approved Health Products under C19RM - COVID-19 Response Mechanism
Principal Recipients are requested to accelerate the procurement of approved health products under C19RM awards through both Pooled Procurement Mechanism (PPM) and non-PPM channels to ensure rapid availability in their countries. -
17 August 2021
The ACT-Accelerator: Diagnostics Pillar Update
Testing is the first line of defense in the fight against COVID-19. Without testing, countries cannot track or contain the spread of the virus, address urgent clinical needs, test the efficacy of vaccines, or detect the emergence of new variants.